FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366254566> ?p ?o ?g. }

• W4366254566 endingPage "57" @default.
• W4366254566 startingPage "49" @default.
• W4366254566 abstract "Eribulin a microtubule targeting agent and analog of Halichondrin B, a natural product isolated from marine sponge H. okadai, has proven clinical efficacy in metastatic pretreated breast cancer and liposarcoma. We conducted a 2-stage Phase II study of eribulin in patients with advanced/recurrent cervical cancer to examine its clinical activity and evaluate biomarkers for predictors of response.Women with advanced/recurrent cervical cancer after ≤1 prior chemotherapy regimen, measurable disease and ECOG performance status ≤2 were treated with eribulin (1.4 mg/m2 IV day 1 and 8, every 21 days) with tumor assessments every 2 cycles. Primary endpoint was 6-month progression-free survival (PFS6); secondary were best overall response (RECISTv1.1), toxicity (CTCAEv4.03) and overall survival (OS). Exploratory endpoints were associations of biomarkers with clinical activity. Immunohistochemistry was performed on archival tumor samples. Overexpression was defined when both intensity and distribution scores were ≥ 2.32 patients enrolled from 11/2012-5/2017. 29/32 patients had prior chemotherapy with cisplatin/paclitaxel/bevacizumab (n = 12) or cisplatin/gemcitabine (n = 12) as the most common regimens. 14 patients received prior paclitaxel. 1 (3%) had a complete response, 5 (16%) had a partial response and 13 (41%) had stable disease for ORR of 19% (95% CI 8, 37). Those who are paclitaxel naïve experienced the greatest benefit with a 29% ORR (95% CI 12, 54). Patients who received prior paclitaxel responded less favorably than those who did not (p = .002) and had a shorter PFS and OS. Grade 3/4 adverse events occurring in >10% of patients were anemia (n = 12, 38%), neutropenia (n = 7, 22%) and leukopenia (n = 6, 19%). Analysis of correlative predictors of response revealed that patients who did not overexpress βII and BAX were significantly more likely to respond to e`ribulin. PFS was significantly shorter in patients with βII and BAX overexpression, OS was significantly shorter in those with βIII and BAX overexpression. These associations remained after multivariate analysis.Eribulin shows modest activity in patients with recurrent/advanced cervical cancer with a favorable toxicity profile. Prior paclitaxel exposure is associated with decreased eribulin response. βII, βIII tubulin subtypes and BAX are predictors of response and survival. Eribulin may be an option for women with paclitaxel-naïve recurrent/advanced cervical cancer." @default.
• W4366254566 created "2023-04-20" @default.
• W4366254566 creator A5002462952 @default.
• W4366254566 creator A5013268286 @default.
• W4366254566 creator A5032677863 @default.
• W4366254566 creator A5040858131 @default.
• W4366254566 creator A5045207018 @default.
• W4366254566 creator A5048722393 @default.
• W4366254566 creator A5054205659 @default.
• W4366254566 creator A5062167990 @default.
• W4366254566 creator A5067387322 @default.
• W4366254566 creator A5067490446 @default.
• W4366254566 creator A5070020348 @default.
• W4366254566 creator A5071585351 @default.
• W4366254566 creator A5075566972 @default.
• W4366254566 creator A5076331258 @default.
• W4366254566 creator A5080397788 @default.
• W4366254566 creator A5082245952 @default.
• W4366254566 creator A5084817134 @default.
• W4366254566 date "2023-06-01" @default.
• W4366254566 modified "2023-10-16" @default.
• W4366254566 title "Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer" @default.
• W4366254566 cites W1542114385 @default.
• W4366254566 cites W1612747797 @default.
• W4366254566 cites W1840778568 @default.
• W4366254566 cites W1857980043 @default.
• W4366254566 cites W1869637333 @default.
• W4366254566 cites W1926137745 @default.
• W4366254566 cites W1932754573 @default.
• W4366254566 cites W1937628254 @default.
• W4366254566 cites W2003187434 @default.
• W4366254566 cites W2017283588 @default.
• W4366254566 cites W2037549607 @default.
• W4366254566 cites W2068307028 @default.
• W4366254566 cites W2074890479 @default.
• W4366254566 cites W2076542620 @default.
• W4366254566 cites W2095832858 @default.
• W4366254566 cites W2100756525 @default.
• W4366254566 cites W2109396510 @default.
• W4366254566 cites W2118508302 @default.
• W4366254566 cites W2126768246 @default.
• W4366254566 cites W2127152525 @default.
• W4366254566 cites W2142915226 @default.
• W4366254566 cites W2169608095 @default.
• W4366254566 cites W2171725862 @default.
• W4366254566 cites W2259955047 @default.
• W4366254566 cites W2526981875 @default.
• W4366254566 cites W2553088533 @default.
• W4366254566 cites W2725369123 @default.
• W4366254566 cites W2740268022 @default.
• W4366254566 cites W2889646458 @default.
• W4366254566 cites W2911188335 @default.
• W4366254566 cites W2925815206 @default.
• W4366254566 cites W3155156689 @default.
• W4366254566 cites W3162733280 @default.
• W4366254566 cites W3200231835 @default.
• W4366254566 cites W4212784899 @default.
• W4366254566 cites W4224286168 @default.
• W4366254566 doi "https://doi.org/10.1016/j.ygyno.2023.02.016" @default.
• W4366254566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37079977" @default.
• W4366254566 hasPublicationYear "2023" @default.
• W4366254566 type Work @default.
• W4366254566 citedByCount "0" @default.
• W4366254566 crossrefType "journal-article" @default.
• W4366254566 hasAuthorship W4366254566A5002462952 @default.
• W4366254566 hasAuthorship W4366254566A5013268286 @default.
• W4366254566 hasAuthorship W4366254566A5032677863 @default.
• W4366254566 hasAuthorship W4366254566A5040858131 @default.
• W4366254566 hasAuthorship W4366254566A5045207018 @default.
• W4366254566 hasAuthorship W4366254566A5048722393 @default.
• W4366254566 hasAuthorship W4366254566A5054205659 @default.
• W4366254566 hasAuthorship W4366254566A5062167990 @default.
• W4366254566 hasAuthorship W4366254566A5067387322 @default.
• W4366254566 hasAuthorship W4366254566A5067490446 @default.
• W4366254566 hasAuthorship W4366254566A5070020348 @default.
• W4366254566 hasAuthorship W4366254566A5071585351 @default.
• W4366254566 hasAuthorship W4366254566A5075566972 @default.
• W4366254566 hasAuthorship W4366254566A5076331258 @default.
• W4366254566 hasAuthorship W4366254566A5080397788 @default.
• W4366254566 hasAuthorship W4366254566A5082245952 @default.
• W4366254566 hasAuthorship W4366254566A5084817134 @default.
• W4366254566 hasConcept C121608353 @default.
• W4366254566 hasConcept C126322002 @default.
• W4366254566 hasConcept C143998085 @default.
• W4366254566 hasConcept C197934379 @default.
• W4366254566 hasConcept C203092338 @default.
• W4366254566 hasConcept C2775930923 @default.
• W4366254566 hasConcept C2776387010 @default.
• W4366254566 hasConcept C2776694085 @default.
• W4366254566 hasConcept C2777292972 @default.
• W4366254566 hasConcept C2777802072 @default.
• W4366254566 hasConcept C2778220009 @default.
• W4366254566 hasConcept C2780258809 @default.
• W4366254566 hasConcept C2781413609 @default.
• W4366254566 hasConcept C31760486 @default.
• W4366254566 hasConcept C530470458 @default.
• W4366254566 hasConcept C535046627 @default.
• W4366254566 hasConcept C71924100 @default.

• next